CliffBio
small molecule

DAPSONE

DAPSONE

Loss of exclusivity—loss of exclusivity
CompanyAlembic →See this company's full patent-cliff portfolio

Drug detail

Brand nameDAPSONE
Active ingredientDAPSONE
Strength7.5%
Dosage formGEL
RouteTOPICAL
ModalitySmall molecule
FDA approvalOctober 2023
Marketing statusRX

More from Alembic

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.